Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial

Interferon-γ (IFNγ) has been studied as a cancer treatment with limited evidence of clinical benefit. However, it could play a role in cancer immunotherapy combination treatments. Despite high expression of immunogenic cancer-testis antigens, synovial sarcoma (SS) and myxoid/round cell liposarcoma (...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Immunol Res
Asıl Yazarlar: Zhang, Shihong, Kohli, Karan, Black, R. Graeme, Yao, Lu, Spadinger, Sydney M., He, Qianchuan, Pillarisetty, Venu G., Cranmer, Lee D., Van Tine, Brian A., Yee, Cassian, Pierce, Robert H., Riddell, Stanley R., Jones, Robin L., Pollack, Seth M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6677581/
https://ncbi.nlm.nih.gov/pubmed/31171504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0940
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller